
The COVID conundrum: loss and lessons learned
Jul 18, 2022 - 00:17:18
Radio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & Podcasts
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic...
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study is an episode from Talking Urology by Talking Urology. In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis ab...
This episode belongs to Talking Urology.
Use the player on this page to stream the episode online.
Published Sep 24, 2019, 00:13:10 long, audio available.
In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.
You can listen to ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study online on Radio and Podcast. Open the player on this page to stream the available audio.
ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study is an episode from Talking Urology by Talking Urology.
This episode is 00:13:10 long.
This episode was published on Sep 24, 2019.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from Talking Urology when more episodes are available from the podcast feed.